• J. Vasc. Surg. · Jan 2009

    The outcome of thoracic endovascular aortic repair (TEVAR) in patients with renal insufficiency.

    • Grace J Wang, Ronald M Fairman, Benjamin M Jackson, Wilson Y Szeto, Alberto Pochettino, and Edward Y Woo.
    • Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. Grace.Wang@uphs.upenn.edu
    • J. Vasc. Surg. 2009 Jan 1; 49 (1): 42-6.

    ObjectiveWe sought to determine the effects of renal insufficiency on thoracic endovascular aortic repair (TEVAR) outcome and to identify predictors for adverse events.MethodsEighty-four patients with renal insufficiency (creatinine >or=1.5 mg/dL) were analyzed from a prospective TEVAR database from April 1, 1999, to January 1, 2008. Patients were subdivided into groups by creatinine level (mg/dL): group 1 (1.5-2.0), group 2 (2.0-3.0), group 3 (>3.0), and group 4 (preoperative dialysis-dependent). Demographics, aneurysm/aortic lesion characteristics, perioperative morbidity, mortality, and follow-up data were compared with 246 control patients (<1.5 mg/dL).ResultsComorbidities were similar between the renal insufficiency and control groups, except for age (74 +/- 8 vs 69 +/- 6 years, P < .0002), male gender (73% vs 58%, P < .02), and presence of peripheral vascular disease (56% vs 38%, P < .005). Mean follow-up was 9 months. The renal insufficiency and control groups had similar aortic pathologies, including fusiform (51% vs 57%) and saccular aneurysms (27% vs 37%). Overall mean serum creatinine and creatinine clearance did not worsen during follow-up. Perioperatively, 18 patients (21%) patients required dialysis. Nine patients (11%) presented a newly acquired need for dialysis. Degree of preoperative renal impairment correlated with increasing dialysis requirement: group 1, 5% (3 of 55); group 2, 25% (3 of 12); group 3, 38% (3 of 8); and group 4, 100% (9 of 9). Three patients did not recover baseline renal function. Contrast type (isosmolar vs hyposmolar) and amount (96 +/- 8 mL vs 100 +/- 8 mL, P = .33) was similar between the dialysis and no-dialysis groups. Renal insufficiency patients had a statistically significant higher rate of major adverse events (25% vs 6.9%, P < .00003), 30-day mortality (11% vs 4.4%, P < .05), and myocardial infarction (6.0% vs 1.0%, P < .013) than controls. One or more major adverse events occurred in 25%, including stroke (6.0%), myocardial infarction (6.0%), and spinal cord ischemia (4.8%). Predictors for adverse events included emergency repair (odds ratio, 3.1; 95% confidence interval, 1.1-8.4; P = 0.037) and baseline creatinine >2.0 (odds ratio, 5.9; 95% confidence interval, 2.1-16.8; P = .001). Age, gender, adjunctive access, type of aortic pathology, and number of device components did not adversely affect outcome.ConclusionPatients with preoperative renal insufficiency maintain renal function after TEVAR. However, this patient population may be susceptible to increased adverse events, with emergency repair and baseline creatinine >2.0 mg/dL serving as strong predictors.

      Pubmed     Free full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.